title: Banff 07 classification of renal allograft pathology: updates and future directions.
abstract: The 9th Banff Conference on Allograft Pathology was held in La Coruna, Spain on June 23-29, 2007. A total of 235 pathologists, clinicians and scientists met to address unsolved issues in transplantation and adapt the Banff schema for renal allograft rejection in response to emerging data and technologies. The outcome of the consensus discussions on renal pathology is provided in this article. Major updates from the 2007 Banff Conference were: inclusion of peritubular capillaritis grading, C4d scoring, interpretation of C4d deposition without morphological evidence of active rejection, application of the Banff criteria to zero-time and protocol biopsies and introduction of a new scoring for total interstitial inflammation (ti-score). In addition, emerging research data led to the establishment of collaborative working groups addressing issues like isolated 'v' lesion and incorporation of omics-technologies, paving the way for future combination of graft biopsy and molecular parameters within the Banff process.
authors.affiliation: Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada. Kim.Solez@ualberta.ca
authors.forename: K
authors.initials: K
authors.lastname: Solez
authors.forename: R B
authors.initials: RB
authors.lastname: Colvin
authors.forename: L C
authors.initials: LC
authors.lastname: Racusen
authors.forename: M
authors.initials: M
authors.lastname: Haas
authors.forename: B
authors.initials: B
authors.lastname: Sis
authors.forename: M
authors.initials: M
authors.lastname: Mengel
authors.forename: P F
authors.initials: PF
authors.lastname: Halloran
authors.forename: W
authors.initials: W
authors.lastname: Baldwin
authors.forename: G
authors.initials: G
authors.lastname: Banfi
authors.forename: A B
authors.initials: AB
authors.lastname: Collins
authors.forename: F
authors.initials: F
authors.lastname: Cosio
authors.forename: D S R
authors.initials: DS
authors.lastname: David
authors.forename: C
authors.initials: C
authors.lastname: Drachenberg
authors.forename: G
authors.initials: G
authors.lastname: Einecke
authors.forename: A B
authors.initials: AB
authors.lastname: Fogo
authors.forename: I W
authors.initials: IW
authors.lastname: Gibson
authors.forename: D
authors.initials: D
authors.lastname: Glotz
authors.forename: S S
authors.initials: SS
authors.lastname: Iskandar
authors.forename: E
authors.initials: E
authors.lastname: Kraus
authors.forename: E
authors.initials: E
authors.lastname: Lerut
authors.forename: R B
authors.initials: RB
authors.lastname: Mannon
authors.forename: M
authors.initials: M
authors.lastname: Mihatsch
authors.forename: B J
authors.initials: BJ
authors.lastname: Nankivell
authors.forename: V
authors.initials: V
authors.lastname: Nickeleit
authors.forename: J C
authors.initials: JC
authors.lastname: Papadimitriou
authors.forename: P
authors.initials: P
authors.lastname: Randhawa
authors.forename: H
authors.initials: H
authors.lastname: Regele
authors.forename: K
authors.initials: K
authors.lastname: Renaudin
authors.forename: I
authors.initials: I
authors.lastname: Roberts
authors.forename: D
authors.initials: D
authors.lastname: Seron
authors.forename: R N
authors.initials: RN
authors.lastname: Smith
authors.forename: M
authors.initials: M
authors.lastname: Valente
mesh_terms: D001706:Biopsy; D002986:Clinical Trials as Topic; D015935:Complement C4b / Q000032:analysis; D006084:Graft Rejection / Q000473:pathology / Q000517:prevention & control; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology / Q000473:pathology*; D010446:Peptide Fragments / Q000032:analysis; D014184:Transplantation, Homologous
chemical_list: D007166:Immunosuppressive Agents; D010446:Peptide Fragments; D015935:Complement C4b; C032261:complement C4d